See other companies on Welcome to the Jungle

Freenome

Biological analysis platform for cancer

Freenome logo
501-1000 employees
  • Healthcare
  • B2B
  • Biology
  • Machine Learning
  • MedTech
The East Side, South San Francisco, CA

Company mission

To reinvent disease management through early detection and precision intervention.

Top investors

Few candidates hear
back within 2 weeks

14% employee growth in 12 months

Our take

Freenome is a biotechnology company offering a biological analysis platform that uses molecular biology and machine learning to detect cancer with a routine blood draw. The platform trains on thousands of cancer-positive blood samples to recognise disease-associated patterns and help detect early-stage cancer, allowing clinicians to optimise treatments.

The company specialises in advanced computational biology, using machine learning to detect patterns among billions of circulating cell-free biomarkers. Freenome continues to focus on the development of its colorectal cancer test, potentially helping the 45 million people not currently up-to-date on colorectal cancer screening guidelines in the United States.

Following its 2022 funding round, the company surpassed the $1 billion funding mark. Freenome is set to accelerate the development of its platform, testing for additional cancers and furthering its blood test detection technology. It's also forming partnerships for R&D purposes, joining forces with health firms such as Geisinger to provide real world data that could help it detect multiple cancers.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Benefits

  • Pre-IPO equity
  • Flexible PTO (exempt) and generous PTO (non-exempt)
  • Comprehensive health coverage, including medical, dental, and vision
  • Wellness and mental health resources, including Employee Assistance Programs (EAPs), Paid maternity and paternity leave
  • 401(k) plan
  • Plus, a variety of other perks, including pre-tax commuter benefits, two paid volunteer days per year, pet insurance, and additional discounts

Funding (last 2 of 7 rounds)

Feb 2024

$254m

LATE VC

Dec 2021

$300m

SERIES D

Total funding: $1.1bn

This company has top investors

Leadership

Studied at Yale, Johns Hopkins and Dartmouth. Was a Thiel Fellow and co-founded Immudicon and Oncolinx.

Jobs (5)

All locations

Software Engineering